2023
Biological treatment for bullous pemphigoid
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Biological treatment for bullous pemphigoid. Frontiers In Immunology 2023, 14: 1157250. PMID: 37180101, PMCID: PMC10172582, DOI: 10.3389/fimmu.2023.1157250.Peer-Reviewed Original ResearchConceptsBullous pemphigoidImmunosuppressive therapyPatients treated with rituximabLong-term corticosteroid useAdjuvant immunosuppressive therapyConventional immunosuppressive therapySteroid-sparing agentsAutoimmune subepidermal bullous diseaseFirst-line treatmentPrevious treatment failuresSeries of patientsFollow-up periodFollow-up visitSignificant side effectsNo adverse eventsSubepidermal bullous diseasesBP durationRecalcitrant BPRituximab coursesSystemic corticosteroidsClinical responseTreatment failureCorticosteroid useImmunobiological therapyBiologic therapy
2016
Is There a Role for Opportunistic Infection Prophylaxis in Pemphigus? An Expert Survey
Leshem Y, Snast I, Friedland R, Atzmony L, Levi A, Hodak E, Mimouni D. Is There a Role for Opportunistic Infection Prophylaxis in Pemphigus? An Expert Survey. American Journal Of Clinical Dermatology 2016, 18: 127-132. PMID: 27826815, DOI: 10.1007/s40257-016-0233-1.Peer-Reviewed Original ResearchConceptsOpportunistic infection prophylaxisImmunosuppressive therapyInfection prophylaxisInitiation of immunosuppressive therapyEffects of immunosuppressive therapyAdverse effects of immunosuppressive therapyEmergence of resistant pathogensCessation of immunosuppressionHistory of OIInfectious disease specialistsDrug of choiceTertiary care settingBackgroundOpportunistic infectionsImmunosuppressive agentsImmunosuppressive conditionsRisk stratificationDisease specialistsFrequent drugsResistant pathogensSide effectsSevere diseaseHepatitis virusObjectiveOur objectivePatientsPemphigus